The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

The Supreme Court’s recent unanimous decision on FDA’s drug-approval authority is utterly unremarkable.

Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the ...

An analysis from the Congressional Budget Office warns that cuts to the National Institutes of Health and FDA drug reviews could significantly reduce the number of new medications reaching the U.S.

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access ...